Pneumonia Testing Market
Number of pages: 100 | Report Format: PDF | Published date: April 18, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 635.7 million |
|
Market Size Value in 2031 |
US$ 1,092.4 million |
|
CAGR |
6.2% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Test Type, Method, Technology, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global pneumonia testing market was valued at US$ 635.7 million in 2022 and is expected to register a revenue CAGR of 6.2% to reach US$ 1,092.4 million by 2031.
Pneumonia Testing Market Fundamentals
Pneumonia testing refers to medical tests used to determine the presence of pneumonia, a lung infection that leads to lung inflammation. Sometimes, a physician may also order a chest CT scan or a bronchoscopy. Pneumonia testing typically involves a physical exam, blood tests, and a chest X-ray. Urine antigen testing has become standard care for identifying Legionella infection. Pneumococcal urine antigen testing is now advised in the Dutch recommendations to streamline antibiotic therapy in patients hospitalized with pneumonia. However, these tests have flaws and might be unable to find specific infections. C-reactive protein measurement is advised in primary care to enhance the prescription of antibiotics for lower respiratory tract infections. Recent developments in molecular testing techniques have opened up new possibilities for diagnosis and made it feasible to identify diseases more quickly. This plays a crucial role in enriching the global pneumonia testing market opportunity. According to recent studies, procalcitonin levels may also aid in distinguishing between viral and bacterial pneumonia, lower the need for antibiotics, and predict the severity of pneumonia. Based on these specific diagnostic tests, the doctor prescribes particular pneumonia treatment, including antibiotics, antiviral medications, or other supportive care measures depending on the cause and severity of the infection.
[12123]
Pneumonia Testing Market Dynamics
The increased prevalence of pneumonia has raised the requirement for precise and fast identification of the condition. Pneumonia is a dangerous respiratory infection that can result in hospitalization and even death, particularly in vulnerable populations, including the elderly and small children. As a result, early detection and treatment are critical for improving patient outcomes and decreasing the burden on healthcare systems. As a result, the emergence of pneumonia is increasing the pneumonia testing market demand, which aids in identifying the causative agent of the disease and providing suitable therapy. The pneumonia testing market trend is also supported by the rising incidence of chronic obstructive pulmonary disease (COPD) and other lung-related illnesses, which raise the risk of pneumonia. According to the World Health Organization (WHO), pneumonia threatens world health, particularly for children under five. It caused 740,180 fatalities globally in 2019, accounting for 14.0% of all infant deaths and 22.0% of all deaths in children between the ages of one and five.
Introducing innovative, sensitive, and focused testing methods is anticipated to increase the precision of pneumonia diagnosis and treatment, resulting in better patient outcomes and a rise in the demand for testing. Moreover, emphasizing pneumonia diagnosis criteria such as cough, expectoration, chest pain, dyspnea, and signs of invasion of the alveolar space also improve disease detection. As a result, the global market revenue for pneumonia testing is expected to grow significantly during the forecast period from 2023 to 2031. Furthermore, introducing rapid diagnostic procedures, including rapid antigen testing by pneumonia testing kits, can yield results in just a few minutes, enabling medical professionals to promptly identify and treat pneumonia in patients. These tests are particularly helpful in resource-constrained environments where access to laboratory facilities may be restricted because they are affordable and simple.
Governmental organizations contribute funds to support the study and creation of cutting-edge pneumonia diagnostic methods. The need for pneumonia testing is ultimately fueled by this improved access to healthcare institutions and implemented pneumonia testing protocol. Many governments enact regulations requiring people to be tested for pneumonia, especially in high-risk groups like the elderly, small children, and people with underlying medical issues. Several governments offer subsidies and incentives to encourage healthcare providers and manufacturers to create more affordable pneumonia testing options. This should enable a greater population to have easier access to testing.
However, the high cost of pneumonia testing kits is a major pneumonia testing market challenge. Due to this difficulty, low-income nations with the highest prevalence of pneumonia have limited access to testing. This problem could be solved, and diagnostic rates could be raised by creating inexpensive, reliable pneumonia testing kits. Additionally, the market can be recaptured by funding research and development to produce more accessible and affordable testing options and by promoting legislative initiatives that give money for pneumonia prevention and treatment a top priority. Collaborations between public health agencies and businesses in the private sector may also help to reduce costs and widen access to testing in underprivileged areas.
Pneumonia Testing Market Ecosystem
This report provides the global pneumonia testing market analysis regarding revenue, market growth, market dynamics, regional landscape, and overall competitive positioning of the major market players. The global pneumonia testing market is analyzed from six perspectives: type, test type, method, technology, end-user, and region.
Pneumonia Testing Market by Type
[7689]
Based on type, the global pneumonia testing market is segmented into bacterial, viral, and others. The bacterial segment is sub-segmented into Streptococcus, Legionella, Chlamydophila, and Mycoplasma.
The bacterial segment accounted for the largest revenue share of the global pneumonia testing market in 2022. Bacterial infections like Legionella and Streptococcus pneumoniae frequently result in pneumonia. Coughing, fever, and breathing difficulties are the most important bacterial pneumonia symptoms. Laboratory procedures that can precisely identify the type of bacteria causing the infection, such as cultures or antigen detection assays, can be used to determine the bacterial type of pneumonia. The most common type of pneumonia is bacterial pneumonia. Pneumococcal pneumonia is the most prevalent kind of bacterial pneumonia. Streptococcus pneumoniae, often in the upper respiratory tract, causes pneumococcal pneumonia. According to the American Lung Association, it affects over 900,000 Americans every year. Making an optimal treatment decision requires an early and precise diagnosis. The presence of bacterial infections can be reliably determined owing to the high sensitivity and specificity of tests for bacterial pneumonia.
Pneumonia Testing Market by Test Type
Based on test type, the global pneumonia testing market is segmented into blood test, sputum test, urine test, and others.
The blood count segment accounts for the largest market revenue share. The most commonly performed pneumonia blood tests include complete blood count (CBC) with the differential and basic metabolic panel. The CBC with differential measures the number and types of blood cells, while the basic metabolic panel measures electrolyte levels, kidney function, and blood glucose levels. These tests can help diagnose and monitor pneumonia and identify any complications or underlying conditions. A blood culture test can reveal whether a bacterial infection has migrated to the blood and the germ, causing pneumonia. This test is critical in deciding which antibiotics should treat pneumonia. It can also assist in determining whether the infection has gotten worse and may now be fatal. Moreover, blood tests can provide information about the severity of pneumonia. For example, an elevated protein level called procalcitonin may indicate a more severe bacterial infection and a higher risk of sepsis.
Pneumonia Testing Market by Method
The global pneumonia testing market is segmented based on the method into Immunodiagnostic, molecular diagnostic, and point-of-care (POC) testing.
The point-of-care (POC) testing segment accounted for the largest revenue share of the global pneumonia testing market in 2022. Point-of-care pneumonia diagnosis is based on immunochromatographic assays for quick antigen recognition of pathogen-specific antigens and real-time PCR testing for pathogen-specific genomic sequence identification. These diagnostic approaches have shown promising accuracy and speed outcomes, enabling early detection and treatment of pneumonia. The FDA has approved three RT-PCR-based point-of-care tests: GeneXpert Flu A/B, Simplexa Flu A/B&RSV, and FilmArray RVP.
Pneumonia Testing Market by Technology
Based on technology, the global pneumonia testing market is segmented into enzyme-linked immunosorbent assay (ELISA), immunofluorescence, immunohistochemistry (IHC), polymerase chain reaction (PCR), and others.
The enzyme-linked immunosorbent assay (ELISA) segment accounted for the largest revenue share of the global pneumonia testing market in 2022. The ELISA test is excellent for detecting Streptococcus pneumoniae in patients with pneumonia. ELISA-measured serum immunoglobulin g response to pneumolysin may thus aid in the laboratory diagnosis of pneumococcal pneumonia. Identifying specific antibodies or antigens in the patient's blood or respiratory secretions is the basis for this procedure because of its sensitivity and specificity. ELISA is a reliable method for the early detection and treatment of pneumococcal pneumonia. This assay may also aid in investigating the occurrence of dual pneumococcal infections. Furthermore, the ELISA test could be used to assess the efficacy of pneumococcal vaccinations in eliciting an immune response against pneumolysin.
Pneumonia Testing Market by End User
Based on the end-user, the global pneumonia testing market is segmented into hospitals, diagnostic centers, and others.
The hospital segment accounted for the largest revenue share of the global pneumonia testing market in 2022. In terms of modern diagnostics, hospitals are the preferred and most efficient location for testing for pneumonia. In addition, hospitals have specialized medical professionals trained to handle and treat extreme cases of pneumonia, ensuring that patients receive the best available diagnosis and treatment. Hospitals also have access to a variety of tools and services that can help in the identification and management of pneumonia.
On the other hand, the diagnostic center segment accounts for the second-largest market revenue share. The rise in revenue share influences the growth of the diagnostic center's segment in diagnostic facilities performing diagnostic procedures, such as microbiological testing from sputum, blood, and urine, especially in emerging nations.
Pneumonia Testing Market by Region
Based on the region, the global pneumonia testing market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America accounted for the largest revenue share of the global pneumonia testing market in 2022. Due to the high prevalence of pneumonia in nations like the US and growing awareness of early-stage diagnosis and testing, the pneumonia testing market size in the area is expected to develop significantly during the forecast period from 2023 to 2031. The Centers for Disease Control and Prevention (CDC) estimated that in 2019, pneumonia caused over 50,000 deaths in Americans. North America has a developed medical infrastructure with cutting-edge lab facilities and highly skilled medical staff. This infrastructure makes the effective detection and treatment of various medical problems possible, influencing North America to account for a large proportion of pneumonia testing market share.
According to the pneumonia testing market analysis report, the market in Asia Pacific is increasing quickly because of numerous factors, such as an increase in the prevalence of pneumonia, a rise in an older population, and various government programs to promote awareness about pneumonia.
Pneumonia Testing Competitive Landscape
Companies across the region are investing in their expansion and growth, which is also expected to improve the pneumonia testing market outlook. Notable market participants operating the global pneumonia testing market include,
Pneumonia Testing Market Strategic Development
Pneumonia testing refers to medical tests used to determine the presence of pneumonia, a lung infection caused by infectious pathogens.
North America is the key growth region in the global pneumonia testing market, with the largest revenue share.
The major restraining factor for the global pneumonia testing market is high cost and lack of knowledge about the diagnosis.
Key companies operating the global pneumonia testing market are Thermo Fisher Scientific Inc., Alere Inc., Quidel Corporation, Becton, Dickinson and Company, and Meridian Bioscience.
The global pneumonia testing market is expected to grow at a revenue CAGR of 6.2% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain